financetom
Business
financetom
/
Business
/
Update: Kohl's Shares Rise After Fiscal Q2 Results, Updated 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Kohl's Shares Rise After Fiscal Q2 Results, Updated 2025 Outlook
Aug 27, 2025 7:46 AM

10:18 AM EDT, 08/27/2025 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)

Kohl's (KSS) shares rose past 23% in recent Wednesday trading after the company released its fiscal Q2 results and revised its fiscal 2025 guidance.

The department store retail chain reported fiscal Q2 adjusted earnings of $0.56 per diluted share, down from $0.59 a year earlier. Analysts polled by FactSet expected $0.30.

Net sales for the quarter ended Aug. 2 were $3.35 billion, compared with $3.53 billion a year earlier. Analysts surveyed by FactSet expected $3.32 billion.

For fiscal 2025, the company said it now expects adjusted EPS of $0.50 to $0.80 on a net sales decline of 5% to 6%, compared with non-GAAP EPS of $0.10 to $0.60 on a sales decline of 5% to 7% expected previously.

Analysts polled by FactSet expect non-GAAP earnings of $0.44 per share.

Price: 16.10, Change: +3.06, Percent Change: +23.47

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data
Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data
Mar 12, 2024
Tuesday, Fractyl Health Inc ( GUTS ) released new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy platform.  RJVA-001 is the company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D. Related Content: Weight-Loss Drug Gold Rush Gets Larger As New Player...
Reunion Gold Announces Acceptance of Terms of Scope for Environmental and Social Impact Assessment on Oko West Project
Reunion Gold Announces Acceptance of Terms of Scope for Environmental and Social Impact Assessment on Oko West Project
Mar 12, 2024
10:52 AM EDT, 03/12/2024 (MT Newswires) -- Reunion Gold Corporation ( RGDFF ) says the Environmental Protection Agency (EPA) of Guyana has finalized and approved the Terms of Scope (ToS) for the Environmental and Social Impact Assessment (ESIA) on the Oko West Project in Guyana's Region 7. The ToS is required for Reunion to move forward with work on the...
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
Mar 12, 2024
10:51 AM EDT, 03/12/2024 (MT Newswires) -- Genprex ( GNPX ) said Tuesday that South Korea's Patent Office has issued it a patent covering the use of its Reqorsa Immunogene Therapy lead drug candidate in combination with anti-PD-1 and PD-L1 antibodies through 2037 to treat cancers. The patent is applicable to the company's Acclaim-2 and Acclaim-3 trials, Genprex ( GNPX...
Broadridge Financial Solutions Launches New SaaS Platform for Enhanced Derivatives Trading
Broadridge Financial Solutions Launches New SaaS Platform for Enhanced Derivatives Trading
Mar 12, 2024
10:52 AM EDT, 03/12/2024 (MT Newswires) -- Broadridge Financial Solutions ( BR ) said Tuesday it launched its global Futures and Options Software-as-a-Service platform to expand its derivatives trading capabilities. The new platform is expected to improve order and execution management capabilities for sell-side institutions, delivering new derivatives trading capabilities for global players in the Futures Commission Merchant community, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved